Negócios · 22/11/20161 min de leitura
E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population; International Council for Harmonisation; Draft Guidance for Industry; Availability
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance entitled "E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population" (E11(R1) addendum). The draft guidance was prepared under the auspices of the International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation. The draft guidance is an addendum to the guidance entitled "E11 Clinical Investigation of Medicinal Products in the Pediatric Population" (ICH E11 guidance). The draft guidance is intended to update the ICH E11 guidance and provide clarification and current regulatory perspective on topics in global pediatric drug development.